$38.910
+0.132 (+0.34%)收盤時
TRS 資訊
TRS 事件
Sees FY26 Sales Growth of 3%-6%
Sees FY26 sales growth 3%-6% year-over-year.
TriMas Reports Q1 Revenue of $168.28M
Reports Q1 revenue $168.28M vs $152.46M last year. "We delivered first quarter results consistent with our expectations, while successfully completing the divestiture of TriMas Aerospace in March, an important milestone in the continued transformation of TriMas," said Thomas Snyder, TriMas President and Chief Executive Officer. "We entered 2026 with a clear focus on strengthening our core businesses, and the decisive cost actions implemented in January are expected to support improved operating leverage as we move through the year. With a more focused portfolio, enhanced financial flexibility and disciplined execution across the organization, we believe TriMas is well positioned to deliver improved performance and drive sustainable long-term value for our stakeholders."
Company Reaffirms 2026 Sales Growth of 3%-6%
The Company is reaffirming the full year 2026 sales and margin outlook previously provided on February 26, 2026. For 2026, the Company continues to expect sales growth of 3% to 6% year-over-year across its combined Packaging and Specialty Products businesses and more than 300 basis points of adjusted operating profit margin improvement, driven by cost reductions and realignment initiatives. In addition, the Company is providing full year 2026 adjusted diluted earnings per share from continuing operations guidance, which is expected to be in the range of $1.50 to $1.70, representing an approximate 191% increase at the midpoint compared to $0.55 in 2025. This outlook assumes approximately $9 million of interest income per each remaining quarter and assumes no significant change in interest rates or the redeployment of the cash proceeds for the remainder of the year.
TriMas Completes Aerospace Divestiture for Approximately $1.45B
TriMas announced that it has completed the previously announced divestiture of the TriMas Aerospace business to PennAero, a portfolio company of Tinicum L.P. and funds managed by Blackstone, Inc. The transaction, first disclosed on November 4, 2025, was completed for approximately $1.45B in cash, subject to customary post-closing adjustments, with estimated net after-tax proceeds of approximately $1.2B. "This transaction represents a significant milestone in TriMas' ongoing transformation, further sharpening our focus and enhancing our financial flexibility," said Thomas Snyder, President and CEO. "As we noted previously, we expect to use the net proceeds to support organic growth investments, pursue strategically aligned acquisition opportunities and repurchase shares. Whether through customer-focused innovation, operational excellence, productivity improvements or strategic acquisitions focused on attractive packaging and life sciences opportunities, this step strengthens our ability to pursue long-term growth that elevates the overall TriMas portfolio. Guided by our Strategic Investment Committee, we will continue to evaluate opportunities that advance our vision for a more customer-centric, growth-focused TriMas, while delivering strong returns for our shareholders."
TriMas Q4 Revenue $155.49M, Below Consensus
Reports Q4 revenue $155.49M, consensus $192.96M. "We finished 2025 with a solid performance at the upper end of our earnings per share guidance range, supported by continued strong top-line growth and disciplined execution across our businesses," said Thomas Snyder, TriMas President and Chief Executive Officer. "Since stepping into the CEO role last June, my focus has been on building momentum and positioning TriMas for its next chapter. Our previously announced Aerospace transaction continues to progress as planned, with completion expected in mid-to-late March. In parallel, we are realigning TriMas for the future, streamlining our operating structure, executing cost-out initiatives and creating a more agile, customer-centric organization. The proceeds of the Aerospace divestiture will enable us to invest in our business, expand further into attractive packaging and life sciences opportunities, accelerate value creation and deliver compelling long-term returns for our shareholders."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。